People: Threshold Pharmaceuticals Inc (THLD.OQ)
THLD.OQ on NASDAQ Stock Exchange Capital Market
5.30USD
1 Aug 2013
5.30USD
1 Aug 2013
Price Change (% chg)
$-0.12 (-2.21%)
$-0.12 (-2.21%)
Prev Close
$5.42
$5.42
Open
$5.48
$5.48
Day's High
$5.48
$5.48
Day's Low
$5.26
$5.26
Volume
125,670
125,670
Avg. Vol
127,854
127,854
52-wk High
$9.28
$9.28
52-wk Low
$3.95
$3.95
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Harold Selick |
57 | Chief Executive Officer, Director | |
Stewart Kroll |
54 | 2011 | Senior Vice President - Biostatistics and Clinical Operations |
Mark Matteucci |
59 | 2007 | Senior Vice President - Discovery Research |
Joel Fernandes |
43 | 2011 | Vice President - Finance, Controller |
Tillman Pearce |
56 | 2012 | Chief Medical Officer |
Jeffrey Bird |
52 | 2008 | Independent Director |
Bruce Cozadd |
49 | 2005 | Independent Director |
David Hoffmann |
68 | 2007 | Independent Director |
Wilfred Jaeger |
44 | 2001 | Independent Director |
George Parker |
74 | 2004 | Independent Director |
David Parkinson |
62 | 2010 | Independent Director |
Laura Hansen |
IR Contact |
Biographies
| Name | Description |
|---|---|
Harold Selick |
Dr. Harold E. Selick, Ph.D., is Chief Executive Officer, Director of Threshold Pharmaceuticals Inc. From June 2002 until July 2007, Dr. Selick was a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, Inc. (now PDL BioPharma, Inc., or PDL) he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL’s first product, Zenapax (daclizumab), which was developed and commercialized by Roche for treating kidney transplant rejection. Dr. Selick serves on the board of directors of PDL, a public company and currently serves as Chairman of the Board of Directors of Catalyst Biosciences, a privately-held drug discovery and development company, serves as a director of InteKrin Therapeutics, a clinical-stage, privately-held biopharmaceutical company, and also serves as a director of Protagonist Therapeutics, a privately-held biotechnology company. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco. |
Stewart Kroll |
Mr. Stewart M. Kroll is Senior Vice President - Biostatistics and Clinical Operations of Threshold Pharmaceuticals Inc. Prior to May 2011, Mr. Kroll served as Vice President of Biostatistics and Clinical Operations. Mr. Kroll served as the Senior Director of Biostatistics of Corixa Corporation from December 2000 to January 2005, and served in positions of increasing responsibility, most recently as Director of Biostatistics of Coulter Pharmaceuticals, Inc. from January 1997 to December 2000. Mr. Kroll received his B.A. and M.A. from the University of California, Berkeley. |
Mark Matteucci |
Dr. Mark D. Matteucci, Ph.D., is Senior Vice President - Discovery Research of Threshold Pharmaceuticals Inc. Prior to January 2007, Dr. Matteucci served as Vice President, Discovery Research. Dr. Matteucci provided medicinal chemistry consultation to several biotechnology companies from 1999 to 2002. He served as the Director of Bioorganic Chemistry at Gilead Sciences, Inc. from 1988 to 1999, where he was the first scientist hired and he established that company’s research program in nucleic acid targeting. Prior to joining Gilead Sciences, Dr. Matteucci was a scientist at Genentech, Inc. Dr. Matteucci received his B.S. from the Massachusetts Institute of Technology and Ph.D. from the University of Colorado. |
Joel Fernandes |
Mr. Joel A. Fernandes is Vice President - Finance, Controller of Threshold Pharmaceuticals Inc. Prior to May 2011, Mr. Fernandes served as Senior Director, Finance and Controller. Mr. Fernandes served as Associate Director of Finance at Theravance, Inc. from January 2005 to March 2006, Senior Manager of Corporate Finance at KLA-Tencor from August 2002 to January 2005 and Assistant Controller of ALZA Corporation from 1999 to 2002. Mr. Fernandes has been a Certified Public Accountant since 1996 and has a Masters in Accountancy from Manchester College, Indiana. |
Tillman Pearce |
Dr. Tillman Pearce, M.D., is Chief Medical Officer of Threshold Pharmaceuticals, Inc. Dr. Pearce served as Chief Medical Officer of KaloBios Pharmaceuticals, Inc., from 2007 through 2011, and since 2011 has been an oncology consultant. Prior to KaloBios, Dr. Pearce was a Senior Director at PDL BioPharma, Inc. from 2002 to 2007 and a Medical Director in the Oncology Business Unit at Sanofi-Synthelabo from 1997 to 2002. He has also held research positions in oncology at Sandoz and Novartis. Dr. Pearce holds a B.A. in philosophy from Tulane University and an M.D. from the Medical College of Georgia. |
Jeffrey Bird |
Dr. Jeffrey W. Bird, M.D., Ph.D., is Independent Director of Threshold Pharmaceuticals Inc. Dr. Bird is a Managing Director of Sutter Hill Ventures, a venture capital firm based in Palo Alto, California. Dr. Bird was previously Senior Vice President, Business Operations at Gilead Sciences, where he oversaw business development and commercial activities. Dr. Bird received a degree in Biological Sciences from Stanford in 1982, a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School. Dr. Bird is currently a board member of Horizon Pharma, Inc., a public company, and a number of private biotechnology companies. |
Bruce Cozadd |
Mr. Bruce C. Cozadd is Independent Director of Threshold Pharmaceuticals Inc. He joined Jazz Pharmaceuticals plc at its inception and was appointed Chairman and Chief Executive Officer in April 2009. From 2004 until 2009, Mr. Cozadd served as Jazz Pharmaceuticals’ Executive Chairman. Prior to co-founding Jazz Pharmaceuticals, Mr. Cozadd served in various executive management positions with ALZA Corporation from 1991 until its acquisition by Johnson & Johnson in 2001. At the time of the merger, Mr. Cozadd was serving as Executive Vice President and Chief Operating Officer of ALZA, with responsibility for research and development, manufacturing, and sales and marketing. Prior to joining ALZA, he was in the Corporate Finance Health Care group at Smith Barney, Harris Upham & Co. Inc. He serves on the board of directors of Jazz Pharmaceuticals, Inc., Cerus Corp., The Nueva School and Stanford Hospital and Clinics. He received his B.S. from Yale University and his M.B.A. from Stanford University. The company board of directors believes that Mr. Cozadd’s leadership experience at other life sciences companies gives him a breadth of knowledge and a unique perspective on the industry. |
David Hoffmann |
Mr. David R. Hoffmann is Independent Director of Threshold Pharmaceuticals Inc. Mr. Hoffmann is retired from ALZA Corporation (now a Johnson & Johnson company) where he held the positions of Vice President and Treasurer from 1992 to until his retirement in October 2002, Vice President of Finance from 1982 to 1992 and Director of Accounting/Finance from 1976 to 1982. Mr. Hoffmann is currently Chief Executive Officer of Hoffmann Associates, a multi-group company specializing in cruise travel and financial and benefit consulting. He serves on the board of directors of DURECT Corporation. Mr. Hoffmann holds a B.S. in Business Administration from the University of Colorado. The company board of directors believes that Mr. Hoffman’s financial knowledge and industry experience are to the board, particularly with respect to his service on the audit committee. |
Wilfred Jaeger |
Dr. Wilfred E. Jaeger, M.D., is Independent Director of Threshold Pharmaceuticals Inc. He has been a Partner of Three Arch Partners, a venture capital firm, since 1993. Dr. Jaeger serves on the board of directors of North American Scientific, Inc. and a number of private companies. Dr. Jaeger received his B.S. from the University of British Columbia, his M.D. from the University of British Columbia School of Medicine and his M.B.A. from Stanford University. The company board of directors has determined to nominate Dr. Jaeger for election as a director as it believes that Dr. Jaeger’s financial and medical knowledge and experience are to the board, particularly with respect to his service on the audit and compensation committees. |
George Parker |
Dr. George G. C. Parker, Ph.D., is Independent Director of Threshold Pharmaceuticals Inc. Dr. Parker is the Dean Witter Distinguished Professor of Finance (Emeritus) and previously Senior Associate Dean for Academic Affairs and Director of the MBA Program, Graduate School of Business, Stanford University. Dr. Parker joined the faculty at Stanford University in 1973. He serves on the board of directors of iShares Mutual Funds, Tejon Ranch Company, Colony Financial, Inc. and First Republic Bank and a number of private companies, and was formerly a director of Continental Airlines, Inc. and Netgear, Inc. Dr. Parker received his B.A. from Haverford College and his M.B.A. and Ph.D. from Stanford University. |
David Parkinson |
Dr. David Ross Parkinson, M.D., is Independent Director of Threshold Pharmaceuticals Inc. He is the president and chief executive officer of Nodality, a South San Francisco-based biotechnology company. Prior to 2007, Dr. Parkinson was senior vice president of Oncology Research and Development at Biogen Idec, vice president of Oncology Development at Amgen and vice president of Global Clinical Oncology Development at Novartis. Dr. Parkinson also worked at the National Cancer Institute from 1990 to 1997, serving as chief of the Investigational Drug Branch, then as action associate director of the Cancer Therapy Evaluation Program. He has also held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center at Tufts University School of Medicine. Dr. Parkinson received his M.D. as gold medalist from the University of Toronto Faculty of Medicine in 1977, with Internal Medicine and Hematology/Oncology training in Montreal at McGill University and in Boston at New England Medical Center. Dr. Parkinson is a past chairman of the Food and Drug Administration (FDA) Biologics Advisory Committee and is a recipient of the FDA’s Cody Medal. He is a past president of the International Society of Biological Therapy and past editor of the Journal of Immunotherapy. He currently serves on the National Cancer Policy Forum of the Institute of Medicine. He has recently completed a term on the FDA’s Science Board as well as a term on the board of directors of the American Association of Cancer Research (AACR). He continues to serve as Chairman of the AACR Finance Committee. The company board of directors has determined to nominate Dr. Parkinson for election in part because it believes it benefits from Dr. Parkinson’s medical knowledge and experience, especially in the field of oncology, and his industry perspective. |
Laura Hansen |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Harold Selick |
1,556,770 |
Stewart Kroll |
602,815 |
Mark Matteucci |
585,221 |
Joel Fernandes |
434,108 |
Tillman Pearce |
565,569 |
Jeffrey Bird |
-- |
Bruce Cozadd |
-- |
David Hoffmann |
-- |
Wilfred Jaeger |
-- |
George Parker |
-- |
David Parkinson |
-- |
Laura Hansen |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Harold Selick |
1,677,257 | 24,180,190 |
Stewart Kroll |
52,481 | 337,521 |
Mark Matteucci |
0 | 0 |
Joel Fernandes |
0 | 0 |
Tillman Pearce |
0 | 0 |
Jeffrey Bird |
0 | 0 |
Bruce Cozadd |
0 | 0 |
David Hoffmann |
0 | 0 |
Wilfred Jaeger |
0 | 0 |
George Parker |
0 | 0 |
David Parkinson |
0 | 0 |
Laura Hansen |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
JAEGER WILFRED E |
84,648 | $5.52 |
JAEGER WILFRED E |
4,552 | $5.52 |
JAEGER WILFRED E |
220,923 | $5.54 |
JAEGER WILFRED E |
11,877 | $5.54 |
JAEGER WILFRED E |
5,918 | $5.52 |
JAEGER WILFRED E |
110,082 | $5.52 |
JAEGER WILFRED E |
3,163 | $5.50 |
JAEGER WILFRED E |
58,837 | $5.50 |
JAEGER WILFRED E |
4,897 | $5.48 |
JAEGER WILFRED E |
91,070 | $5.48 |
JAEGER WILFRED E |
117,389 | $5.56 |
JAEGER WILFRED E |
6,311 | $5.56 |
JAEGER WILFRED E |
1,898 | $5.50 |
JAEGER WILFRED E |
102 | $5.50 |
SELICK HAROLD E |
19,607 | $1.86 |
JAEGER WILFRED E |
50,865 | $5.50 |
JAEGER WILFRED E |
2,735 | $5.50 |
JAEGER WILFRED E |
94,898 | $5.47 |
JAEGER WILFRED E |
5,102 | $5.47 |
GAITHER JAMES C |
11,729 | $1.86 |
BIRD JEFFREY W |
38,747 | $1.86 |
PULLARA SAMUEL J III |
260,592 | $5.72 |
BAKER G LEONARD JR |
18,939 | $1.86 |
ANDERSON DAVID L |
500 | $5.72 |
BAKER G LEONARD JR |
801,952 | $1.86 |

